BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
Keyword: Rifaximin
1
Exploring effectiveness of Metronidazole, Bismuth, and Rifaximin in treating small intestinal bacterial overgrowth and irritable bowel syndrome: A systematic review
2/10/2026 10:35:31 AM | Browse: 21 | Download: 105
2
Rifaximin and sarcopenia in cirrhosis: Commentary on a promising but complex relationship
9/25/2025 11:24:01 AM | Browse: 114 | Download: 183
3
Incidence and efficacy of strategies for preventing hepatic encephalopathy following transjugular intrahepatic portosystemic shunt: A meta-analysis
4/25/2025 8:23:03 AM | Browse: 105 | Download: 461
4
Rifaximin-α use is associated with improved muscle mass in patients with cirrhosis
4/25/2025 8:23:02 AM | Browse: 102 | Download: 579
5
Rifaximin on epigenetics and autophagy in animal model of hepatocellular carcinoma secondary to metabolic-dysfunction associated steatotic liver disease
1/23/2024 9:31:45 AM | Browse: 561 | Download: 1530
6
Evaluation of a protocol for rifaximin discontinuation in critically ill patients with liver disease receiving broad-spectrum antibiotic therapy
11/24/2023 6:10:12 AM | Browse: 293 | Download: 1107
7
Evolution of care in cirrhosis: Preventing hepatic decompensation through pharmacotherapy
1/4/2023 5:53:01 AM | Browse: 570 | Download: 1406
8
Evidence-based approach to management of hepatic encephalopathy in adults
4/22/2022 10:52:23 AM | Browse: 658 | Download: 1241
9
Effect of a specific Escherichia coli Nissle 1917 strain on minimal/mild hepatic encephalopathy treatment
3/24/2022 2:13:21 PM | Browse: 671 | Download: 2322
10
Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care
5/14/2020 3:43:04 AM | Browse: 1102 | Download: 2577
11
Rifaximin improves survival in cirrhotic patients with refractory ascites: A real-world study
1/13/2020 11:27:13 AM | Browse: 1121 | Download: 2409
12
Lessons from “real life experience” of rifaximin use in the management of recurrent hepatic encephalopathy
1/3/2020 1:28:57 AM | Browse: 1038 | Download: 2053
13
Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
6/27/2019 10:40:37 AM | Browse: 1033 | Download: 2635
14
Current and future pharmacological therapies for managing cirrhosis and its complications
2/27/2019 4:11:15 AM | Browse: 1344 | Download: 2122
15
Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
12/20/2017 2:49:19 AM | Browse: 1527 | Download: 2880
16
Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation
7/7/2017 11:41:16 AM | Browse: 1422 | Download: 2315
17
Advances in cirrhosis: Optimizing the management of hepatic encephalopathy
12/10/2015 3:04:00 PM | Browse: 1355 | Download: 2136
18
Spontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liver
12/2/2015 12:01:00 PM | Browse: 1590 | Download: 1988
19
Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications
11/24/2015 3:55:00 PM | Browse: 1492 | Download: 2592
20
Rifaximin and Crohn's disease
9/12/2014 8:41:00 PM | Browse: 1296 | Download: 1301
21
Clinical update for the diagnosis and treatment of Clostridium difficile infection
9/5/2014 2:44:00 PM | Browse: 1613 | Download: 1677
22
Second and third line treatment options for Helicobacter pylori eradication
9/3/2014 10:14:00 AM | Browse: 1395 | Download: 1338
23
Irritable bowel syndrome: A concise review of current treatment concepts
8/25/2014 5:12:00 PM | Browse: 1369 | Download: 1481
Write to the Help Desk
© 1993-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

California Corporate Number: 3537345